Technology area: Biotechnology & Pharmaceuticals
16 pending office actions • 13 art units • 15 examiners • 0 of 16 (0%) have an AI response strategy ready • 28 patents granted in the last 365 days
Kyungpook National University Industry - Academic Cooperation Foundation has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to a distinct examiner within a distinct art unit. LIU, SUE XU is the busiest examiner for the portfolio, overseeing the 1 pending office action. This reflects a very specific and limited scope of current patent activity for the foundation. Practitioners should focus their strategy on the specific preferences of this individual examiner, as all current activity is under her review.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 4 (25%) |
| §103 only | 6 (38%) |
| Double-patenting + other | 1 (6%) |
| Multi-statute (no §101) | 5 (31%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MEJIAS, SAMANTHA LEE | 2 | 46.7% | +40.0% |
| WHITE, DYLAN C | 1 | 77.1% | +13.3% |
| FAN, LYNN Y | 1 | 47.3% | +49.8% |
| HUTSON, RICHARD G | 1 | 65.1% | +52.9% |
| UNDERDAHL, THANE E | 1 | 58.8% | +50.2% |
| SEAMAN, D MARGARET M | 1 | 76.6% | +8.1% |
| MAYHEW, BRADLEY SCOTT | 1 | 0.0% | +0.0% |
| ZHANG, RUIYUN | 1 | 70.3% | +10.7% |
| BUCKMASTER, MARLENE VRENI | 1 | 28.1% | +74.3% |
| MUI, CHRISTINE T | 1 | 78.4% | +19.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19207336 | APPARATUS AND METHOD FOR CHARGING AND DISCHARGING SCHEDULING OF ELECTRIC VEHICLE | WHITE, DYLAN C | — |
| 19099080 | METHOD FOR LIQUEFYING AGAROSE AND PRODUCING NEOAGAROTETRAOSE/NEOAGAROHEXAOSE BY USING THERMOSTABLE GH16B BETA-AGARASE DERIVED FROM NOVEL AGAR-DEGRADING BACTERIUM | HUTSON, RICHARD G | — |
| 18706564 | GH117A a-NEOAGAROBIOSE HYDROLASE DERIVED FROM A NOVEL AGAR-DEGRADING BACTERIUM AND PRODUCING METHOD OF L-AHG USING THE SAME | UNDERDAHL, THANE E | — |
| 18840293 | COMPOSITION FOR PROMOTING COLLAGEN PRODUCTION COMPRISING AMIDATED AMINO ACID | SEAMAN, D MARGARET M | — |
| 18290754 | GADOLINIUM-BASED COMPOUND, AND MRI CONTRAST AGENT INCLUDING SAME | MEJIAS, SAMANTHA LEE | — |
| 18515486 | COMPOSITION FOR INHIBITING SKIN PIGMENTATION THROUGH AUTOPHAGY ACTIVITY CONTAINING PROCYANIDIN A2 AND QUERCETIN, AS ACTIVE INGREDIENTS | MAYHEW, BRADLEY SCOTT | — |
| 18286082 | COMPOUND HAVING THERMOTROPIC LIQUID CRYSTALLINE STRUCTURE, AND POLYETHYLENE GLYCOL POLYMER THEREOF | ZHANG, RUIYUN | — |
| 18022050 | COMPOSITION FOR DIAGNOSING INFECTIOUS DISEASES COMPRISING AGENT FOR MEASURING EXPRESSION LEVEL OF SREBP2 | BUCKMASTER, MARLENE VRENI | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17422052 | METHOD FOR SYNTHESIZING HYALURONIC ACID NANOPARTICLES, AND HYALURONIC ACID NANOPARTICLES PREPARED BY METHOD | MEJIAS, SAMANTHA LEE | 15d overdue |
| 18147872 | DISEASE DIAGNOSIS KIT, DISEASE DIAGNOSIS METHOD USING THE DISEASE DIAGNOSIS KIT AND METHOD FOR MANUFACTURING THE DISEASE DIAGNOSIS KIT | MUI, CHRISTINE T | 42d |
| 19207336 | APPARATUS AND METHOD FOR CHARGING AND DISCHARGING SCHEDULING OF ELECTRIC VEHICLE | WHITE, DYLAN C | — |
| 19057133 | Beauveria Bassiana KNU-101 Strain Having Excellent Insecticidal Effect and Sporulation Potential and Use Thereof | FAN, LYNN Y | — |
| 19099080 | METHOD FOR LIQUEFYING AGAROSE AND PRODUCING NEOAGAROTETRAOSE/NEOAGAROHEXAOSE BY USING THERMOSTABLE GH16B BETA-AGARASE DERIVED FROM NOVEL AGAR-DEGRADING BACTERIUM | HUTSON, RICHARD G | — |
| 18706564 | GH117A a-NEOAGAROBIOSE HYDROLASE DERIVED FROM A NOVEL AGAR-DEGRADING BACTERIUM AND PRODUCING METHOD OF L-AHG USING THE SAME | UNDERDAHL, THANE E | — |
| 18290754 | GADOLINIUM-BASED COMPOUND, AND MRI CONTRAST AGENT INCLUDING SAME | MEJIAS, SAMANTHA LEE | — |
| 18286082 | COMPOUND HAVING THERMOTROPIC LIQUID CRYSTALLINE STRUCTURE, AND POLYETHYLENE GLYCOL POLYMER THEREOF | ZHANG, RUIYUN | — |
| Art Unit | Apps |
|---|---|
| 1652 | 2 |
| 1618 | 2 |
| 1677 | 2 |
| 3625 | 1 |
| 1653 | 1 |
| 1625 | 1 |
| 1621 | 1 |
| 1782 | 1 |
| 1672 | 1 |
| 1797 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19207336 | APPARATUS AND METHOD FOR CHARGING AND DISCHARGING SCHEDULING OF ELECTRIC VEHICLE | WHITE, DYLAN C | 3625 | §101§102 | Non-Final OA | — | Pending | May 13, 2025 |
| 19057133 | Beauveria Bassiana KNU-101 Strain Having Excellent Insecticidal Effect and Sporulation Potential and Use Thereof | FAN, LYNN Y | 1653 | §103 | Non-Final OA | — | Pending | Feb 19, 2025 |
| 19099080 | METHOD FOR LIQUEFYING AGAROSE AND PRODUCING NEOAGAROTETRAOSE/NEOAGAROHEXAOSE BY USING THERMOSTABLE GH16B BETA-AGARASE DERIVED FROM NOVEL AGAR-DEGRADING BACTERIUM | HUTSON, RICHARD G | 1652 | §103§112 | Non-Final OA | — | Pending | Jan 28, 2025 |
| 18706564 | GH117A a-NEOAGAROBIOSE HYDROLASE DERIVED FROM A NOVEL AGAR-DEGRADING BACTERIUM AND PRODUCING METHOD OF L-AHG USING THE SAME | UNDERDAHL, THANE E | 1652 | §101§102§103§112 | Non-Final OA | — | Pending | Oct 10, 2024 |
| 18840293 | COMPOSITION FOR PROMOTING COLLAGEN PRODUCTION COMPRISING AMIDATED AMINO ACID | SEAMAN, D MARGARET M | 1625 | §101§102§112 | Non-Final OA | — | Pending | Aug 21, 2024 |
| 18290754 | GADOLINIUM-BASED COMPOUND, AND MRI CONTRAST AGENT INCLUDING SAME | MEJIAS, SAMANTHA LEE | 1618 | §103§112 | Non-Final OA | — | Pending | Jul 25, 2024 |
| 18515486 | COMPOSITION FOR INHIBITING SKIN PIGMENTATION THROUGH AUTOPHAGY ACTIVITY CONTAINING PROCYANIDIN A2 AND QUERCETIN, AS ACTIVE INGREDIENTS | MAYHEW, BRADLEY SCOTT | 1621 | §102§103 | Non-Final OA | — | Pending | Nov 21, 2023 |
| 18286082 | COMPOUND HAVING THERMOTROPIC LIQUID CRYSTALLINE STRUCTURE, AND POLYETHYLENE GLYCOL POLYMER THEREOF | ZHANG, RUIYUN | 1782 | §102§103 | Final Rejection | — | Pending | Oct 06, 2023 |
| 18022050 | COMPOSITION FOR DIAGNOSING INFECTIOUS DISEASES COMPRISING AGENT FOR MEASURING EXPRESSION LEVEL OF SREBP2 | BUCKMASTER, MARLENE VRENI | 1672 | §101§112 | Final Rejection | — | Pending | Feb 17, 2023 |
| 18147872 | DISEASE DIAGNOSIS KIT, DISEASE DIAGNOSIS METHOD USING THE DISEASE DIAGNOSIS KIT AND METHOD FOR MANUFACTURING THE DISEASE DIAGNOSIS KIT | MUI, CHRISTINE T | 1797 | §103 | Final Rejection | 42d | Pending | Dec 29, 2022 |
| 17985129 | TOXICITY EVALUATION SYSTEM AND METHOD FOR TOXICOLOGICAL EVALUATION USING THE SAME | GIERE, REBECCA M | 1677 | §102§103§112 | Final Rejection | — | Pending | Nov 10, 2022 |
| 17843418 | PD-1-DECORATED NANOCAGES AND USES THEREOF | KOMATSU, LI N | 1658 | §103 | Final Rejection | 3d overdue | Pending | Jun 17, 2022 |
| 17825935 | DIAGNOSIS METHOD USING PLASMON PHENOMENON, DIAGNOSTIC KIT AND MANUFACTURING METHOD OF DIAGNOSTIC KIT | OGUNTADE, ELIZABETH BISOLA | 1677 | §103 | Non-Final OA | 34d | Pending | May 26, 2022 |
| 17642250 | USE OF ENDOTHELIN RECEPTOR INHIBITOR FOR INHIBITING EXOSOME SECRETION OR INHIBITING PD-L1 EXPRESSION | BUNKER, AMY M | 1684 | §103 | Non-Final OA | — | Pending | Mar 11, 2022 |
| 17629607 | BIOCOMPATIBLE HYDROGEL COMPRISING HYALURONIC ACID AND POLYETHYLENE GLYCOL | MATTISON, LORI K | 1619 | §103DP | Non-Final OA | 96d overdue | Pending | Jan 24, 2022 |
| 17422052 | METHOD FOR SYNTHESIZING HYALURONIC ACID NANOPARTICLES, AND HYALURONIC ACID NANOPARTICLES PREPARED BY METHOD | MEJIAS, SAMANTHA LEE | 1618 | §103 | Final Rejection | 15d overdue | Pending | Jul 09, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKyungpook National University Industry-Academic Cooperation Foundation has 16 pending office actions as of October 2026, spread across 13 art units and 15 examiners.
Samantha Lee Mejias has the most, with 2 of Kyungpook National University Industry-Academic Cooperation Foundation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
